-
Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology
From VEGF-targeted agents to immune-based combinations and novel HIF-2α inhibitors, the expanding therapeutic arsenal for renal cell carcinoma (RCC) has significantly prolonged patient survival. At the same time, it has posed a more demanding challenge for clinicians: how to tailor the optimal treatment for each individual patient and truly achieve precision medicine.
-
Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer
In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier –…
-
Professor Ng Chi Fai: New Advances in Adjuvant Therapy for Renal Cell Carcinoma and Optimization of Clinical Decision-Making | 15th Shanghai Academic Conference on Urologic Oncology
For many years, adjuvant therapy for renal cell carcinoma (RCC) remained in a state of “therapeutic vacuum.” RCC is intrinsically resistant to radiotherapy and chemotherapy, and early attempts to introduce targeted therapies into the adjuvant setting failed to deliver meaningful benefits. The success of the KEYNOTE-564 trial has been a turning point—ushering RCC adjuvant therapy…
-
Voice of China at ASH |Professor Wang Hui / Wang Dongchu: From MRD Monitoring to Early CRS Identification—Unlocking New Paradigms in Immunologic Diagnosis and Therapy
From December 6 to 10, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. The meeting highlighted the latest advances in both clinical hematology and basic research, driving progress in the diagnosis and treatment of hematologic diseases as well as translational research.In this issue, we feature the…
-
Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA, from December 6 to 9, 2025, bringing together the latest research advances and clinical progress in hematology worldwide. At this year’s meeting, Professor Wang Huafeng’s team from The First Affiliated Hospital, Zhejiang University School of Medicine had six studies…
-
Individualized Treatment of Prostate Cancer and Clinical Management of NHT-Related Adverse Effects
In the era of precision medicine for prostate cancer, individualized clinical decision-making has become a central focus of daily practice. At a recent academic conference on urologic oncology, Professor Hailiang Zhang from Huadong Hospital affiliated with Fudan University shared his clinical perspectives on novel hormonal therapy (NHT) in metastatic prostate cancer. He emphasized that, based…
-
Breakthroughs by Chinese Investigators in the Treatment of Metastatic Urothelial Carcinoma
At a recent academic conference on urologic oncology, Professor Jun Guo from Peking University Cancer Hospital & Institute delivered an important presentation systematically reviewing the ten-year journey of Chinese researchers in the field of drug therapy for urothelial carcinoma (UC)—from following international trends to taking a leading role. His lecture focused on the landmark achievements…
-
Professor Jingjing Wang Provides an In-Depth Analysis of Precision Strategies and PARP Inhibitor–Based Combinations in Prostate Cancer
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting convened leading experts in urologic oncology from across China to discuss cutting-edge diagnostic and therapeutic strategies for genitourinary malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer. During the conference, Professor Jingjing Wang, representing the field of…
Connecting Medical Expertise through Media